Company CEO has said they expect to know if the vaccine works by the end of October
WEDNESDAY, Oct. 28, 2020 (HealthDay News) — In November, Pfizer plans to ask the U.S. Food and Drug Administration for emergency authorization for its COVID-19 vaccine after safety milestones are achieved, CBS News reported Tuesday.
Pfizer said its final vaccine trial has enrolled almost all of the planned 44,000 participants worldwide. Nearly 36,000 had received the second shot of the vaccine as of Monday. The trial includes people as young as 12 years and those with chronic, stable HIV, hepatitis C, and hepatitis B, CBS News reported.
Pfizer expects to know soon if the vaccine is effective or not — Pfizer CEO Albert Bourla had said they expect to know if the vaccine works by the end of October.
The company has contracts with the United States, the European Union, and about 10 countries to deliver hundreds of millions of doses of the vaccine next year, assuming it is approved, CBS News reported.
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease 
Trends Reported in Vaccination Coverage for Adolescents for 2025 
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season 
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer 
Retinal Imaging Can ID Atrial Fibrillation Years Before Diagnosis 
U.S. Adults May Not Understand Their Risk for Vascular Disease 
Lower Breast, Cervical Cancer Screening Seen for Adults With Disabilities 
Screening + Online Cognitive Behavioral Therapy Program Aids Nurses" Mental Health 
